{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bonduelle O"],"funding":["SANOFI PASTEUR S.A."],"pagination":["e184128"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12016920"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(8)"],"pubmed_abstract":["BACKGROUNDThe high-dose quadrivalent influenza vaccine (QIV-HD) showed superior efficacy against laboratory-confirmed illness compared with the standard-dose quadrivalent influenza vaccine (QIV-SD) in randomized controlled trials with the elderly. However, specific underlying mechanism remains unclear.METHODSThis phase IV randomized controlled trial compared early innate responses induced by QIV-HD and QIV-SD in 59 individuals aged > 65 years. Systemic innate cells and gene signatures at day 0 (D0) and D1 as well as hemagglutinin inhibition antibody (HIA) titers at D0 and D21 after vaccination were assessed.RESULTSQIV-HD elicited robust humoral response with significantly higher antibody titers and seroconversion rates than QIV-SD. At D1 after vaccination, QIV-HD recipients showed signific"],"journal":["JCI insight"],"pubmed_title":["Boosting effect of high-dose influenza vaccination on innate immunity among elderly."],"pmcid":["PMC12016920"],"funding_grant_id":["E003603032"],"pubmed_authors":["Bonduelle O","Bennacer S","Combadiere B","Alves K","INFLUOMICS Study group","Janssen C","Rogeaux O","Ghidi M","Wokam M","Lenormand M","de Bernard S","Lina B","Petrier M","Delory T","Franco-Moscardini I","Nourikyan J"],"additional_accession":[]},"is_claimable":false,"name":"Boosting effect of high-dose influenza vaccination on innate immunity among elderly.","description":"BACKGROUNDThe high-dose quadrivalent influenza vaccine (QIV-HD) showed superior efficacy against laboratory-confirmed illness compared with the standard-dose quadrivalent influenza vaccine (QIV-SD) in randomized controlled trials with the elderly. However, specific underlying mechanism remains unclear.METHODSThis phase IV randomized controlled trial compared early innate responses induced by QIV-HD and QIV-SD in 59 individuals aged > 65 years. Systemic innate cells and gene signatures at day 0 (D0) and D1 as well as hemagglutinin inhibition antibody (HIA) titers at D0 and D21 after vaccination were assessed.RESULTSQIV-HD elicited robust humoral response with significantly higher antibody titers and seroconversion rates than QIV-SD. At D1 after vaccination, QIV-HD recipients showed signific","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-02T04:15:04.261Z","creation":"2025-07-06T03:04:08.684Z"},"accession":"S-EPMC12016920","cross_references":{"pubmed":["40036077"],"doi":["10.1172/jci.insight.184128"]}}